Pulse Brain · Growing Health Evidence Index
Peer-reviewed

Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer

Yingtao Lin, Chang Wang, Xiaoyan He, Qimin Yao, Jian Chen

Frontiers in Immunology · 2024

Read source ↗ All evidence

Summary

Introducing pembrolizumab alongside chemotherapy and bevacizumab may not be a cost-effective primary strategy for advanced cervical cancer against current standards. However, for patients with a PD-L1 CPS ≥10, the therapeutic and economic outcomes could be improved by adjusting the pembrolizumab price.

Source type
Peer-reviewed study
DOI
10.3389/fimmu.2023.1345942
Catalogue ID
SNmoht1vsb-l98v98
Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.

How does this finding apply in a UK context?→What are the most cited records on this topic?→